abrocitinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Atopic Dermatitis

Pending FDA approval for moderate-to-severe atopic dermatitis

Next:

Pharmacology

Mechanism of Action

Janus kinases (JAKs) pathways inhibitor; JAK consists of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoieses and immune cell function

Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression; JAK inhibitors modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs

These signals are essential in maintaining the inflammatory condition in atopic dermatitis; inhibition of JAKs reduces production of and modulates proinflammatory cytokines

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.